Download Documentation Baird’s 2016 Global Healthcare Conference
Download Documentation Keryx Corporate Presentation

Corporate Profile

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our 17-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston, New York, and our field team.

Stock Quote

KERX (Common)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.25 (5.68%)
Data as of 10/20/16 3:06 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Report

View the 2015 Annual Report on Form 10K  - PDF View the 2015 Annual Report on Form 10K

Recent News

10/14/16Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual MeetingPrinter Friendly Version
09/21/16Keryx Biopharmaceuticals to Webcast its Presentation at Ladenburg Thalmann’s 2016 Healthcare ConferencePrinter Friendly Version
09/01/16Keryx Biopharmaceuticals to Present at Two Upcoming Investor Healthcare ConferencesPrinter Friendly Version
08/01/16Keryx Biopharmaceuticals Announces Interruption in Supply of Auryxia® (ferric citrate) and Second Quarter 2016 Financial ResultsPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.